Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study The article by Fietkau et al entitled “Benefit ...

Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial Forty-three evaluable patients with common/pre-B (n ...

In this study, researchers reported on 10-year follow-up of a phase 3 trial comparing surgery to chemoradiation boost in resectable, advanced NSCLC.

CHICAGO -- Patients with undetectable disease after induction therapy for newly diagnosed multiple myeloma (NDMM) did not have significantly better outcomes with a stem-cell transplant versus drug ...

For younger, fit patients with mantle cell lymphoma (MCL), adding the Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib to standard induction therapy with bendamustine/rituximab followed by ...

Data from this new study suggest that tailoring induction therapy for acute myeloid leukemia (AML) based on cytarabine pharmacogenomic 10–single-nucleotide variant score could better treatment for ...

Even in nonproliferative class 1-2 LN, glucocorticoid monotherapy may be insufficient to prevent long-term renal damage. Combination therapy should be considered. Patients with class 1-2 lupus ...

Please provide your email address to receive an email when new articles are posted on . Concomitant use of common medications did not significantly affect treatment efficacy or safety during UC ...